Expansion of iPSC Product Line and Commercial Operations Facilitated by Secured Funding (Pluristyx)
In a significant move for the field of genetically engineered therapies, Pluristyx has completed a funding round led by BioLife Solutions and BroadOak Capital Partners. This investment will contribute to the exploration of biological assays as a potential product portfolio adjacency.
The funding will aid in the growth and commercialization of the PluriForm kit, a turnkey solution that simplifies the generation of organoids and complex test systems for researchers. The latest advancements linked to this funding include the launch of the PluriForm Organoid Kit, which addresses key research bottlenecks in organoid development for disease modeling, drug discovery, and regenerative medicine.
The PluriForm Organoid Kit, introduced by Pluristyx in June 2025, enables precise genetic modifications via CRISPR-Cas9, creating gene-altered organoids. These are instrumental for modeling genetic diseases, tumorigenesis, and testing therapeutic candidates, leading to deeper mechanistic insights and helping identify new therapeutic options.
Pluristyx's immediate access to GMP-standard iPSC lines, like PSXi013, supports drug screening, toxicity assessments, and clinical-grade cell therapy development. This fosters accelerated and standardized advanced therapies.
The company's CEO, Benjamin Fryer, PhD, expressed excitement about the funding round and the support from BioLife Solutions and BroadOak Capital Partners. Pluristyx is differentiated by its suite of proprietary technologies in the iPSC field, which are crucial for developing new medicines and can replace animal models in toxicology, safety, and efficacy assays.
The investors, BioLife Solutions and BroadOak Capital Partners, have a high regard for Pluristyx's scientific expertise in cell therapy. They acknowledge the critical scientific challenges addressed by Pluristyx's proprietary technologies in the iPSC field. The new capital will be used to expand Pluristyx's inventory of clinical-grade iPSC lines with proprietary FailSafe and iACT engineering, and hypoimmune genetic edits.
The advanced cells aim to support next-generation, genetically engineered therapies that are safe, effective, and scalable. This investment strengthens Pluristyx's position as a leader in high-quality stem cell provision. BioLife Solutions is excited to continue its support for Dr. Fryer and the Pluristyx team.
Daniel Friedman, Principal at BroadOak Capital Partners, supports the Pluristyx team. The investors are interested in exploring biological assays as a potential product portfolio adjacency, aligning with the expanding cellular reprogramming tools market that is embracing AI and gene-editing technologies such as CRISPR/Cas systems to optimize gene therapy manufacturing and therapeutic development pipelines.
The funding round is ongoing, with the continued support of its CEOs. Pluristyx's contributions to the cutting edge of genetically engineered therapies by providing tools and standardized cell lines that support more efficient and precise therapeutic solutions in gene and cell therapy complement overall industry trends of AI integration, precise gene editing, and personalized medicine in regenerative and gene therapies.
The investment from BioLife Solutions and BroadOak Capital Partners will help Pluristyx in exploring biological assays as a potential product portfolio adjacency, expanding the company's inventory of clinical-grade iPSC lines for medical-condition research and health-and-wellness applications. The advancements from this funding, such as the PluriForm Organoid Kit, could lead to deeper scientific insights and new therapeutic options for various genetic diseases and medical-conditions.
){kind=link}